|
Jul 2
|
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
|
|
Jun 30
|
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
|
|
Jun 29
|
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
|
|
Jun 27
|
Exploring Three High Growth Tech Stocks In The US Market
|
|
Jun 27
|
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
|
|
Apr 24
|
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
|
|
Apr 23
|
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
|
|
Feb 20
|
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
|
|
Sep 27
|
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability
|
|
Sep 13
|
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
|
|
Sep 12
|
Aurinia Announces Board Restructuring
|
|
Aug 28
|
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 1
|
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
|
|
Aug 1
|
Aurinia: Q2 Earnings Snapshot
|
|
Aug 1
|
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
|
|
Jun 14
|
Aurinia Announces 2024 Annual General Meeting Results
|
|
May 14
|
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
|
|
May 9
|
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
|
|
May 7
|
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
|
|
May 7
|
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
|